Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Accelereret klapdækning ved alvorlige underekstremitetstraumer (FLAP ATTACK)

15. september 2026 opdateret af: Johns Hopkins University

Accelereret klapdækning versus standard timing ved behandling af svære muskel- og skeletskader i underekstremiteterne

The goal of this randomized controlled trial is to determine if accelerated flap coverage compared to standard flap coverage timing leads to improved infection-related complications in patients with open fractures and/or dislocations below the knee. Eligible patients will be randomized to receive either a flap within a goal of 72 hours of injury or standard of care flap timing for the institution. The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility).

This is the vanguard and international part of the FLAP ATTACK trial.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Infection following severe lower extremity musculoskeletal injuries is a challenging problem. Several factors hypothesized to influence infection have been explored and, in many cases, optimized or found not to be influential. A persistent area of uncertainty and variability is the timing of acute soft tissue coverage. In the United States, the mean time to coverage from injury is 10 days, and infection rates are 20-35%. In the United Kingdom, there are national guidelines to support coverage within 72 hours of injury, and infection rates are less than 10%. While the data to support early coverage is promising, the necessary evidence to make this significant change is lacking. To justify the mobilization of resources and expense required to shift practice, a definitive trial is needed. This trial seeks to fill this critical knowledge gap.

The primary objective of this trial is to determine if accelerated flap coverage (within 72 hours of injury) compared to standard flap coverage timing leads lower rates of infection and infection-related complications. The trial population includes patients 18 years and older with an acute open fracture and/or dislocation below the knee, with a diagnosed need for acute soft tissue coverage with a flap. Patients who undergo primary amputation prior to attempted flap coverage will be excluded. There will be 356 participants randomized in 1:1 ratio to receive either accelerated flap coverage (goal of flap within 72 hours from injury) or flap coverage at the time that reflects the standard of care at each institution. The timing of the trial interventions, other adjunctive treatments, the fracture fixation, and flap coverage procedures will be documented for both treatment groups. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. Participants will have follow-up at 6 weeks, 3 months, 6 months, and 12 months post-randomization.

The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility). The secondary outcomes will independently assess the individual components of the primary outcome at 6 and 12 months, the composite outcome at 12 months, and health-related quality of life and patient satisfaction over 6 and 12 months. An Adjudication Committee will review primary and secondary endpoints and a Data Safety Monitoring Committee (DSMC) will review all safety events.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

356

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Victoria
      • Melbourne, Victoria, Australien, 3004
        • Rekruttering
        • The Alfred Hospital
        • Kontakt:
          • Lipi Shukla, MBBS, PhD
        • Ledende efterforsker:
          • Lipi Shukla, MBBS, PhD
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 1N1
        • Rekruttering
        • Vancouver General Hospital
        • Kontakt:
    • New Brunswick
      • Saint John, New Brunswick, Canada, E2L 4L2
        • Rekruttering
        • Saint John Regional Hospital
        • Kontakt:
    • California
      • Sacramento, California, Forenede Stater, 95817
        • Rekruttering
        • UC Davis Medical Center
        • Kontakt:
          • Ara A Salibian, MD
        • Ledende efterforsker:
          • Ara A Salibian, MD
        • Ledende efterforsker:
          • Augustine M Saiz, MD
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21287
        • Rekruttering
        • The Johns Hopkins Hospital
        • Kontakt:
          • Lily R Mundy, MD
        • Ledende efterforsker:
          • Lily R Mundy, MD
      • Baltimore, Maryland, Forenede Stater, 21224
        • Rekruttering
        • John Hopkins Bayview Medical Center
        • Kontakt:
          • Lily R Mundy, MD
        • Ledende efterforsker:
          • Lily R Mundy, MD
      • Baltimore, Maryland, Forenede Stater, 21201
        • Rekruttering
        • R Adams Cowley Shock Trauma Center
        • Kontakt:
          • Mark J Gage, MD
        • Ledende efterforsker:
          • Mark J Gage, MD
      • Largo, Maryland, Forenede Stater, 20774
        • Rekruttering
        • University of Maryland Capital Region Medical Center
        • Kontakt:
          • Todd Jaeblon, MD
        • Ledende efterforsker:
          • Todd Jaeblon, MD
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239
        • Rekruttering
        • Oregon Health & Science University
        • Kontakt:
          • Graham J DeKeyser, MD
        • Ledende efterforsker:
          • Graham J DeKeyser, MD
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37232
        • Rekruttering
        • Vanderbilt University Medical Center
        • Kontakt:
          • Lauren M Tatman, MD
        • Ledende efterforsker:
          • Lauren M Tatman, MD
      • Barcelona, Spanien, 08035
        • Rekruttering
        • Vall d'Hebron University Hospital
        • Kontakt:
          • Jordi Tomás-Hernández, MD
        • Ledende efterforsker:
          • Antonio Bulla, MD, PhD
        • Ledende efterforsker:
          • Jordi Tomás-Hernández, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

The inclusion criteria are:

  1. Patients 18 years of age or older.
  2. Severe lower extremity open fracture and/or dislocation below the knee requiring an acute flap for management of the musculoskeletal injury.
  3. Will have all planned flap surgeries performed by a participating surgeon or delegate.
  4. Able to be randomized within 48 hours of injury.

The exclusion criteria are:

  1. Site is unable to implement the accelerated flap protocol due to local logistics.
  2. Primary amputation anticipated prior to attempted flap for management of the injury.
  3. Critical limb ischemia that requires re-vascularization for limb perfusion.
  4. Chronic or acute infection at or near the musculoskeletal injury site at the time of initial injury surgery.
  5. Burns at the musculoskeletal injury site.
  6. Incarceration.
  7. Expected injury survival of less than 12 months.
  8. Terminal illness with expected survival of less than 12 months.
  9. Currently enrolled in a trial that does not permit co-enrollment.
  10. Declined to provide informed consent.
  11. Unable to obtain informed consent due to language barriers.
  12. Unable to obtain informed consent because a legally authorized representative was unavailable.
  13. Anticipated problems, in the judgment of research personnel, with maintaining follow-up with the patient.
  14. Prior enrollment in the trial.
  15. Eligible patient or LAR was not approached within screening window (missed participant).
  16. Other reason to exclude the patient, as approved by the Principal Investigators.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Accelerated Flap Coverage

Accelerated flap surgery timing at a goal of within 72 hours from injury. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups.

Timing of the flap surgery is with a goal of 72 hours from injury

Aktiv komparator: Standard of Care Flap Timing

The flap surgery will be performed at the standard of care timing for the institution. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups.

Timing of the flap surgery is the standard of care flap timing for the participating institution.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Clinical status
Tidsramme: 6 months

Clinical status is a hierarchical composite of the following outcomes:

  1. All-cause mortality
  2. Amputation related to injury
  3. Re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure)
  4. Days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility)
6 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mortality
Tidsramme: 6 months and 12 months

All-cause mortality. Mortality will be time-to-event, with the assumption that earlier is worse than later.

6 months and 12 months
Amputation
Tidsramme: 6 months and 12 months

Amputation related to injury. Amputation will be time-to-event, with the assumption that earlier is worse than later.

6 months and 12 months
Unplanned re-operation
Tidsramme: 6 months and 12 months

Unplanned re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure). Re-operation for infection and major flap complication will account for more than one operation, assuming that more operations are worse.

6 months and 12 months
Number of days in hospital
Tidsramme: 6 months and 12 months

Days in an acute in-patient hospital (i.e., not rehab or nursing facility)

6 months and 12 months
Patient-reported health status as assessed by the Euro-QoL (EQ-5D-5L)
Tidsramme: 6 months and 12 months

Patient-reported health status as assessed by the EQ-5D-5L. The EQ-5D-5L is scored on a 0 to 100 mm scale. 0 mm represents "the worst health you can imagine to 100 mm which represents "the best health you can imagine".

6 months and 12 months
Quality of life as assessed by the Limb-Q
Tidsramme: 6 months and 12 months

Health-related quality of life and patient satisfaction measured with the Limb-Q. The Limb-Q is a set of independently functioning scales. All scales are scored 0-100 (higher = better). The Limb-Q Appearance, Physical, Symptoms, Financial Impact, Life Impact, and Psychological scales will be used.

6 months and 12 months
Clinical Status
Tidsramme: 12 months

Clinical status is a hierarchical composite of the following outcomes: 1. All-cause mortality 2. Amputation related to injury 3. Re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure) 4. Days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility)

12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Lily Mundy, MD, Johns Hopkins School of Medicine

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

4. november 2024

Primær færdiggørelse (Anslået)

1. august 2029

Studieafslutning (Anslået)

1. februar 2030

Datoer for studieregistrering

Først indsendt

28. februar 2024

Først indsendt, der opfyldte QC-kriterier

28. februar 2024

Først opslået (Faktiske)

5. marts 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • IRB00434587

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .